EP Vantage
EP Vantage
Stop FollowingEP Vantage
ABOUT
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
SNAPSHOT
- Description: Journalist. Trading frequency: Not Trading
- Interests: Dividend stock ideas & income, Stocks - long, Stocks - short
COMPANY
EP Vantage EP Vantage is a new forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of ...More
regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
BLOG
Currently, there are no blog details for EP Vantage.
Book
Currently, there are no book details for EP Vantage.
Latest Comments
more »
- Sorry, that $80m figure act... on Depomed Gains Gabapentin Approval as Abbott Spa...
Latest comments on EP Vantage's Articles
- 6228371 on Biotech Bulls Can Ignore The Warning Signs At T...
- mark woods on Biotech Bulls Can Ignore The Warning Signs At T...
- Rootarmo on Biotech Bulls Can Ignore The Warning Signs At T...
- Giveras on Biotech Bulls Can Ignore The Warning Signs At T...
- Navy on Biotech Bulls Can Ignore The Warning Signs At T...
LATEST ARTICLES & INSTAPOSTS
more »
